Literature DB >> 29777419

Bevacizumab rechallenge in glioblastoma patients with initial response to bevacizumab who later progress off therapy.

Carmen Balana1, Anna Estival2, Estela Pineda3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29777419     DOI： 10.1007/s11060-018-2902-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  2 in total

1.  Outcome of discontinuing bevacizumab prior to malignant glioma progression.

Authors:  Wendy J Sherman; Jeffrey J Raizer; Sean A Grimm
Journal:  J Neurooncol       Date:  2012-10-12       Impact factor: 4.130

2.  Rechallenge with bevacizumab in patients with glioblastoma progressing off therapy.

Authors:  Charlotte Bronnimann; Cristina Izquierdo; Stéphanie Cartalat; Laure Thomas; Bastien Joubert; Laura Delpech; Marc Barritault; David Meyronet; Jérôme Honnorat; François Ducray
Journal:  J Neurooncol       Date:  2018-01-31       Impact factor: 4.130
  2 in total
  1 in total

1.  Coactosin-Like Protein (COTL1) Promotes Glioblastoma (GBM) Growth in vitro and in vivo.

Authors:  Shike Shao; Yongjun Fan; Chongpei Zhong; Xianlong Zhu; Jiaqiu Zhu
Journal:  Cancer Manag Res       Date:  2020-10-30       Impact factor: 3.989
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.